VBI Vaccines Announces Closing of $13.6 Million Private Placement
June 21, 2016
MSK client VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing a next generation of vaccines, proudly announced this week the closing of an equity private placement financing. Under the terms of the financing, VBI sold an aggregate of 3,269,688 of its common shares at a price of approximately $4.16 per share for total gross proceeds of approximately $13.6 million.
MSK served as VBI’s legal counsel in the financing and was led by Kevin Friedmann, Chairman of the Corporate & Business Transactions Department.